Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centersCédric Rossi, Hervé Ghesquières|American Journal of Hematology|2018Cited by 120
Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA studyVincent Camus, Hervé Tilly, Laure Lebras et al.|Blood Advances|2021Cited by 51
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemiaCharles Herbaux, Matthew S. Davids, Christoph Kornauth et al.|Blood|2021Cited by 37
High <i>PDL1/PDL2</i> gene expression correlates with worse outcome in primary mediastinal large B-cell lymphomaVincent Camus, Fabrice Jardin, Pierre‐Julien Viailly et al.|Blood Advances|2023Cited by 17
R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa CentersVincent Camus, Hervé Tilly, Alina Berriolo-Riedinger et al.|Blood|2020Cited by 3